HC Wainwright Forecasts Strong Price Appreciation for Tempus AI (NASDAQ:TEM) Stock

Tempus AI (NASDAQ:TEM) had its target price raised by equities researchers at HC Wainwright from $89.00 to $95.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 87.88% from the company’s previous close.

Several other research firms have also recently weighed in on TEM. Needham & Company LLC lowered their price target on Tempus AI from $100.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Robert W. Baird began coverage on Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target for the company. Morgan Stanley reduced their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $78.62.

Tempus AI Stock Down 3.2%

Shares of Tempus AI stock traded down $1.70 during trading hours on Monday, reaching $50.56. The company’s stock had a trading volume of 3,035,985 shares, compared to its average volume of 5,725,345. The company has a market capitalization of $9.04 billion, a P/E ratio of -35.82 and a beta of 5.29. The stock’s fifty day simple moving average is $60.14 and its two-hundred day simple moving average is $72.59. Tempus AI has a one year low of $36.22 and a one year high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Insider Activity at Tempus AI

In related news, EVP Andrew Polovin sold 10,949 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares in the company, valued at approximately $7,654,424.58. This represents a 7.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the transaction, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This represents a 15.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 590,109 shares of company stock valued at $37,056,566 in the last ninety days. 26.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares during the last quarter. ARK Investment Management LLC boosted its position in Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares during the period. GC Wealth Management RIA LLC bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Tempus AI by 1.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after buying an additional 41,728 shares during the last quarter. Finally, Amova Asset Management Americas Inc. grew its stake in Tempus AI by 1.2% in the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.